Skip to content
ADMETatlas
peptide evidence atlas
Home
About
Home

Browse

PeptidesProductsEvidenceContext signalsDescriptors

Developability

ProfileComparator

Resources

ManualExplanationsStatisticsDownloadLicenseAbout
  1. Home
  2. Peptides
  3. Desmopressin
Peptide·plain sequence-like

Desmopressin

ATLPC0029647

Routes
Compare in workbenchDownload releaseAPI JSON
On this page
  • 01 Sequence & molecular identity
  • 02 Physicochemical profile
  • 03 Exposure / Absorption
  • 04 Distribution / Barrier
  • 05 Excretion / Persistence
  • 06 Evidence landscape
  • 07 Product context
  • 08 Identity & reference map
  • 09 Data access & reproducibility
Coveragecounts only · not riskATLPC0029647
  • Measurements
    15
  • Endpoints
    6
  • Domains
    3/5
  • Products
    1
  • No matrix stability evidence
  • 4 clearance measurements
  • Product-level review pending
  • No sequence liability cues
Jump to domain

Open the matching evidence section below

All evidence index · 15
Exposure / Absorption
8 measurements
Distribution / Barrier
3 measurements
Metabolic & Proteolytic Stability
No evidence
Excretion / Persistence
4 measurements
Toxicity / Safety
No evidence
01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

No reviewed sequence representation available

This peptide currently has identity-level evidence, but no reviewed sequence, HELM, or SMILES representation for residue-level interpretation.

Structure & chemistry

·
Chemical representationnone
Representation class

How the current release can interpret this identity chemically.

plain sequence-like
Parent-residue sequence

Residue string used for positional interpretation when available.

Not available
HELM

Polymer notation for modified peptide representation when available.

Not available
SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available
No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached
3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modifications1 signal
FeaturePositionsInterpretationLink
Form-level topologyATLPF0004946Disulfide-constrained form. Residue-level connection endpoints are shown separately when available.Not linked
02

Physicochemical profile

6 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Physicochemical descriptors unavailable

These descriptors require a standard parent-residue sequence. The module remains visible so modified or unresolved identities are not forced into unreliable computed values.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Structure-derived (developability)

Computed from the representative peptidoform's chemical structure. Rule-of-5 / beyond-Ro5 framing per Lipinski/Doak.

Topological polar surface area
435.4 Ų
Computed logP (Crippen)
-4.13

Computed logP — distinct from the measured logD endpoint.

Hydrogen-bond donors
14
Hydrogen-bond acceptors
15
Rotatable bonds
19
Rule-of-5 / beyond-Ro5 flags
Beyond bRo5

3 Ro5 violations · MW 1,069.24 Da

03

Exposure / Absorption

8 records

What evidence describes systemic exposure or absorption?

Evidence records
8
Complete canonical measurements and observations attached to this domain.
Endpoint scope
3
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
2
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
6
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeBioavailabilityCmaxTmax
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
2
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
6
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Bioavailability5 records · 1 matched-context · 4 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

0.1 %

Eligible when experimental context matches

Bioavailability in rat administered i.d. · rat

Result: Reported point value · Molecular form: not reported · bioavailability · F· Bioavailability in rat administered i.d. · Exact ChEMBL pref name DE... · Source: Primary reference linked

Reference
2

~ 5 %

Use only explicitly reported fields

human

Result: Approximate quantitative measurement · Molecular form: ATLPF0004946 · Route: oral · Desmopressin· Clinical Pharmacology · desmopressin tablet bioavailability relative to int... · Source: Primary reference linked

Reference
3

~ 0.16 %

Use only explicitly reported fields

human

Result: Approximate quantitative measurement · Molecular form: ATLPF0004946 · Route: oral · Desmopressin· Clinical Pharmacology · desmopressin tablet bioavailability relative to int... · Source: Primary reference linked

Reference
4

3.3-4.1 %

Use only explicitly reported fields

Not specified

Result: Interval measurement · Molecular form: not reported · Route: INTRANASAL · 28 · Desmopressin · exact product name match · exact or normalized match · Source: Primary reference linked

Source record
5

0.08-0.16 %

Use only explicitly reported fields

Not specified

Result: Interval measurement · Molecular form: not reported · Route: ORAL · 28 · Desmopressin · exact product name match · exact or normalized match · Source: Primary reference linked

Source record
Cmax1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

0.7482 nM

Eligible when experimental context matches

Cmax value administered intraintestinal in rats. · rat

Result: Reported point value · Molecular form: not reported · max concentration · Cmax· Cmax value administered intraintestinal in rats. · Exact ChEMBL... · Source: Primary reference linked

Reference
Tmax2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

1.5 hours

5400 seconds
Use only explicitly reported fields

human · plasma

Result: Reported point value · Molecular form: ATLPF0004946 · Route: intranasal · Desmopressin· Clinical Pharmacology · desmopressin tmax intranasal · The time to reach ma... · Source: Primary reference linked

Reference
2

0.9 hours

3240 seconds
Use only explicitly reported fields

human · plasma

Result: Reported point value · Molecular form: ATLPF0004946 · Route: oral · Desmopressin· Clinical Pharmacology · desmopressin tmax oral · The time to reach maximum... · Source: Primary reference linked

Reference
04

Distribution / Barrier

3 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records
3
Complete canonical measurements and observations attached to this domain.
Endpoint scope
2
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
2
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
1
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopePlasma protein bindingVd
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
2
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
1
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Vd1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

0.3 L/kg

Eligible when experimental context matches

Volume of distribution at steady state in human after iv administration · human

Result: Reported point value · Molecular form: not reported · Route: iv · volume of distribution · Vdss· Volume of distribution at steady state in human after iv a... · Source: Primary reference linked

Reference
Plasma protein binding2 records · 1 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

41 %

Eligible when experimental context matches

Protein binding in rat plasma at 200 to 1000 ng/ml measured after 15 mins by UC-LC/MS/MS analysis · rat · plasma

Result: Reported point value · Molecular form: not reported · plasma protein binding · PPB· Protein binding in rat plasma at 200 to 1000 ng/ml measured... · Source: Primary reference linked

Reference
2

17.3 %

Use only explicitly reported fields

plasma protein

Result: Reported point value · Molecular form: not reported · Route: NASAL, ORAL, SL, IV, IM, SC · 28 · Desmopressin · exact product name match · exact or normalized match · Source: Primary reference linked

Source record
Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA
0

artificial membrane

Caco-2
0

cell monolayer

MDCK
0

cell monolayer

RRCK
0

cell monolayer

BBB
0

barrier evidence

05

Excretion / Persistence

4 records

What evidence describes clearance or persistence?

Evidence records
4
Complete canonical measurements and observations attached to this domain.
Endpoint scope
1
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
4
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
0
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeClearance
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
4
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
0
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Clearance4 records · 4 matched-context · 0 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

1.4 mL/min/kg

Eligible when experimental context matches

Clearance in human after iv administration · human

Result: Reported point value · Molecular form: not reported · Route: iv · clearance · CL· Clearance in human after iv administration · Exact ChEMBL pref name DESMO... · Source: Primary reference linked

Reference
2

1.7 mL/min/kg

Eligible when experimental context matches

Clearance in iv dosed over hydrated human · human

Result: Reported point value · Molecular form: not reported · Route: iv · clearance · CL· Clearance in iv dosed over hydrated human · Exact ChEMBL pref name DESMOP... · Source: Primary reference linked

Reference
3

7.5 mL/min/kg

Eligible when experimental context matches

Clearance in Sprague-Dawley rat at 0.1 mg/kg, iv administered as cassette dose by LC-MS/MS analysis · rat

Result: Reported point value · Molecular form: not reported · Route: iv · clearance · CL· Clearance in Sprague-Dawley rat at 0.1 mg/kg, iv administered as cassette... · Source: Primary reference linked

Reference
4

7.5 mL/min/kg

Eligible when experimental context matches

Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus dose · rat

Result: Reported point value · Molecular form: not reported · Route: iv · clearance · CL· Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette... · Source: Primary reference linked

Reference
06

Evidence landscape

15 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain
Eligible when context matches
Interpret as reported
Supporting context only
Review before analysis
Exposure / Absorption
8 evidence records
2
6
0
0
Distribution / Barrier
3 evidence records
2
1
0
0
Metabolic & Proteolytic Stability
0 evidence records
0
0
0
0
Excretion / Persistence
4 evidence records
4
0
0
0
Toxicity / Safety
0 evidence records
0
0
0
0
Endpoint distribution

Top evidence-bearing endpoint questions.

Bioavailability
5
Clearance
4
Plasma Protein Binding
2
Time To Max Concentration
2
Max Concentration
1
Volume Of Distribution
1
Assay context

Broad context buckets, useful before comparing values.

In vivo / route
15
Traceability

Reference-link availability for measurement-level audit.

Linked reference
15
Not linked
0
All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

#ADMET domainEndpointReported valueResult typeAnalysis useAssay / modelConditionReference
1
Distribution / Barrier
Distribution
Plasma Protein Binding
17.3 %
Reported point valueUse only explicitly reported fieldsplasma proteinRoute: NASAL, ORAL, SL, IV, IM, SC
Source record
Primary reference linked
2
Exposure / Absorption
Exposure
Bioavailability
3.3-4.1 %
Interval measurementUse only explicitly reported fieldsNot specifiedRoute: INTRANASAL
Source record
Primary reference linked
3
Exposure / Absorption
Exposure
Bioavailability
0.08-0.16 %
Interval measurementUse only explicitly reported fieldsNot specifiedRoute: ORAL
Source record
Primary reference linked
4
Exposure / Absorption
Exposure
Max Concentration
0.748 nM
Reported point valueEligible when experimental context matchesCmax value administered intraintestinal in rats. · ratchembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein
Reference
Primary reference linked
5
Exposure / Absorption
Exposure
Bioavailability
0.1 %
Reported point valueEligible when experimental context matchesBioavailability in rat administered i.d. · ratchembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein
Reference
Primary reference linked
6
Distribution / Barrier
Distribution
Volume Of Distribution
0.3 L/kg
Reported point valueEligible when experimental context matchesVolume of distribution at steady state in human after iv administration · humanRoute: iv · chembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein
Reference
Primary reference linked
7
Excretion / Persistence
Persistence
Clearance
1.4 mL/min/kg
Reported point valueEligible when experimental context matchesClearance in human after iv administration · humanRoute: iv · chembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein
Reference
Primary reference linked
8
Excretion / Persistence
Persistence
Clearance
7.5 mL/min/kg
Reported point valueEligible when experimental context matchesClearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus dose · ratRoute: iv · chembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein
Reference
Primary reference linked
9
Excretion / Persistence
Persistence
Clearance
7.5 mL/min/kg
Reported point valueEligible when experimental context matchesClearance in Sprague-Dawley rat at 0.1 mg/kg, iv administered as cassette dose by LC-MS/MS analysis · ratRoute: iv · chembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein
Reference
Primary reference linked
10
Distribution / Barrier
Distribution
Plasma Protein Binding
41 %
Reported point valueEligible when experimental context matchesProtein binding in rat plasma at 200 to 1000 ng/ml measured after 15 mins by UC-LC/MS/MS analysis · rat · plasmachembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein
Reference
Primary reference linked
1–10 / 15
07

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

·
Summary1 linked product
Linked products
1
Label context
None
Clinical trials
26
Safety label cues
None
Linked products1 shown

Desmopressin

Peptide-product match
Reviewed peptide match
Route / product class
Not resolved in this release
Clinical context
26 trial records · 12 exact intervention matches · 4 with results · latest 2026-04-09
Label safety context
No label safety cue linked
View product
08

Identity & reference map

15 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

·
Summary6 reference groups
Identity type
identity record
Reported notation
1
Reference groups
6
Measurements
15
ATL peptide ID
ATLPC0029647
Identity concordance
Identity concordance
Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 15
Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 15
Different notation

Reported notation does not resolve to the current display sequence.

3 / 15
Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

12 / 15
Reported sequence notation
Different3 references
XYFQNCPrG-NH2
Current identity
No sequence representation
Reported names
No distinct human-readable aliases are exposed.
Reference map6 reference groups
Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

ReferenceSupportsReported identityRecords
Reference
Open
Exposure
Bioavailability, Time To Max Concentration
No reported alias
4 identity
4 evidence
Source record
Open
DistributionExposure
Bioavailability, Plasma Protein Binding
No reported alias
XYFQNCPrG-NH2different
3 identity
3 evidence
Reference
Open
DistributionPersistence
Clearance, Plasma Protein Binding
No reported alias
3 identity
3 evidence
Reference
Open
Exposure
Bioavailability, Max Concentration
No reported alias
2 identity
2 evidence
Reference
Open
DistributionPersistence
Clearance, Volume Of Distribution
No reported alias
2 identity
2 evidence
Reference
Open
Persistence
Clearance
No reported alias
1 identity
1 evidence
09

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

·
Record scopePublic release
ATL peptide ID
ATLPC0029647
Identity type
identity record
ADMET endpoints
6
Evidence records
15
Reference groups
6
Release view
Public release
Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements
Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint
GET /api/v1/peptides/ATLPC0029647
open
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0029647' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'
ADMETatlas
peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse
PeptidesProductsEvidenceContext signalsDescriptors
Resource
DevelopabilityComparatorManualExplanationsStatisticsDownloadAbout
Stack
  • RDKit
  • Mol*
  • Python
  • FastAPI
  • PostgreSQL
  • Next.js
  • React
  • TypeScript
  • Tailwind CSS
  • Apache ECharts
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.